Press releases
- Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
- Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
- Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Key statistics
On Tuesday, Relmada Therapeutics Inc (4E2:FRA) closed at 3.58, 64.22% above the 52 week low of 2.18 set on Jun 28, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.58 |
---|---|
High | 3.58 |
Low | 3.58 |
Bid | 3.62 |
Offer | 3.68 |
Previous close | 3.70 |
Average volume | 0.00 |
---|---|
Shares outstanding | 30.17m |
Free float | 27.69m |
P/E (TTM) | -- |
Market cap | 116.77m USD |
EPS (TTM) | -3.28 USD |
Data delayed at least 15 minutes, as of Apr 23 2024 07:00 BST.
More ▼